Pricing Log in Create free account
Friday 6 November 2026 Export LQDA’s income statement to Excel — free account

Liquidia Corporation

LQDA Healthcare Drug Manufacturers Specialty & Generic

Liquidia Corporation’s revenue for fiscal 2025 (year ended December 2025) was $158.3 million, up 1,031.2% from fiscal 2024.

Revenue
+1,842.7%
EPS
+271.4%
Free cash flow
+270.2%
Total debt
−9.04%

Quarter to June 2026, against a year earlier

44.69 2.69 −5.68%
Market cap
$4.0B
P/E
28.5×
Fwd P/E
22.1×
Dividend yield
—
F-score
5/9
Altman Z
4.08
Beneish M
6.79
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Liquidia Corporation (LQDA) Price to free cash flow

Alert me on Price to free cash flow

As of 5 November 2026, Liquidia Corporation (LQDA) trades at a price to free cash flow of 26.4×. Over the past ten years it has ranged from 0.0× (March 2026) to 167× (June 2026); the current reading is higher than 94% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 16.3× and above the Healthcare sector median of 21.1×.

Price to free cash flow, daily

Embed this chart

Annual newest first

Period Price to free cash flow Change
FY2025 0.0× —
FY2024 0.0× —
FY2023 0.0× —
FY2022 0.0× —
FY2022 0.0× —
FY2021 0.0× —
FY2021 0.0× —
FY2020 0.0× —
FY2020 0.0× —
FY2019 0.0× —

Quarterly newest first

Period Price to free cash flow Change
Jun 2026 47.0× (41.74%)
Mar 2026 80.7× —
Dec 2025 0.0× —
Sep 2025 0.0× —
25 more quarters

Against its own ten years

Low 0.0× High 167×
Ten-year median 0.0×
Current reading's percentile 94

Price to free cash flow against peers

Company Price to free cash flow
AMRX AMNEAL PHARMACEUTICALS, INC. compare n/m
RGC Regencell Bioscience Holdings Limited compare n/m
HCM HUTCHMED (China) Limited Sponsored ADR compare n/m
AMLX Amylyx Pharmaceuticals, Inc. compare n/m
PBH Prestige Consumer Healthcare Inc. compare 9.9×
LNTH Lantheus Holdings, Inc. compare 16.9×
LQDA Liquidia Corporation 26.4×
HIMS Hims & Hers Health, Inc. compare 67.3×
SUPN Indivior Pharmaceuticals Inc. compare 115×
Drug Manufacturers Specialty & Generic industry median 16.3×
Healthcare sector median 21.1×
Market median 14.1×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

More on LQDA